T. Wert

Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis.

S. Corman, N. Joshi, A. Zeidan, 2020, Clinical lymphoma, myeloma & leukemia.

Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis.

S. Corman, N. Joshi, A. Zeidan, 2020, Clinical lymphoma, myeloma & leukemia.

Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes.

J. Schmier, M. Botteman, M. Karimi, 2022, Clinical lymphoma, myeloma & leukemia.

Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes

P. Lefebvre, F. Laliberté, W. Cheng, 2021, Hematology.